Sponsors / MSLE
MSLE

Satellos Bioscience, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
2Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101NCT06867107MSLEPhase 2Enrolling by invitation2027-09-30Estimated
Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsNCT07287189MSLEPhase 2Recruiting2027-03-31Estimated

Latest recorded trial changes

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

NCT06867107 · Satellos Bioscience, Inc.

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Treatment emergent adverse events

+ After

Measure: Treatment emergent adverse events Measure: SAT-3247 effect on fat fraction in biceps brachii

Planned enrollment increased by 20 participants

− Before

10 participants (planned)

+ After

30 participants (planned)

Primary completion date changed

− Before

30 Aug 2026

+ After

30 Sep 2027

Check registry source